• Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans

Subscribe to Updates

Get the latest finance news and updates directly to your inbox.

Top News

10 Car Brands With the Highest Repair Costs in the Long Run — and the 3 Cheapest

December 18, 2025

Marrying for Money Works: 6 Ways Marriage Builds Wealth

December 18, 2025

Pain Power

December 18, 2025
Facebook Twitter Instagram
Trending
  • 10 Car Brands With the Highest Repair Costs in the Long Run — and the 3 Cheapest
  • Marrying for Money Works: 6 Ways Marriage Builds Wealth
  • Pain Power
  • Musk predicts AI will create ‘universal high income’ and make saving money unnecessary
  • Mortgage rates tick higher but remain near 2025 lows
  • 3 Ways to Build a Lasting Legacy of Generosity
  • 3 Reasons I Hate Crypto — and 3 Reasons I Own It Anyway
  • The Top 10 Jobs You Can Find in the Health Care Industry Now
Thursday, December 18
Facebook Twitter Instagram
FintechoPro
Subscribe For Alerts
  • Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans
FintechoPro
Home » ADRs End Mostly Higher, Missfresh and Mesoblast Trade Actively
Investing

ADRs End Mostly Higher, Missfresh and Mesoblast Trade Actively

News RoomBy News RoomAugust 7, 20231 Views0
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email Tumblr Telegram

By Denny Jacob

International stocks trading in New York closed mostly higher on Friday.

The S&P/BNY Mellon index of American depositary receipts edged up 0.2% to 156.41. The European index ticked up 0.1% to 149.96. The Asian index climbed 0.3% to 183.83. The Latin American index slipped 0.7% to 202.40, while the emerging-markets index was flat at 303.65.

Missfresh was among those whose ADRs traded actively.

The Chinese online grocery company soared 285% after it reported share-purchase agreements with two investors, an acquisition and the filing of its delayed 2022 annual report.

Mesoblast tumbled 59% after the Food and Drug Administration once again turned away the company’s remestemcel-L drug candidate for children with a potentially life-threatening bone marrow transplant complication, calling on the company to provide more data.

Write to Denny Jacob at [email protected]

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Articles

Even Time-Strapped Business Owners Can Share an Engaging Reading Experience with Their Kids

Investing September 20, 2025

Turnover Is Costing You More Than You Think — Here’s the Fix

Investing September 19, 2025

How Pana Food Truck Started Selling Arepas

Investing September 18, 2025

Amazon CEO Andy Jassy Is Fighting Against Bureaucracy

Investing September 17, 2025

Here Are the Top 50 Mistakes I’ve Seen Kill New Companies

Investing September 16, 2025

Google Parent Alphabet Reaches $3T Market Cap

Investing September 15, 2025
Add A Comment

Leave A Reply Cancel Reply

Demo
Top News

Marrying for Money Works: 6 Ways Marriage Builds Wealth

December 18, 20250 Views

Pain Power

December 18, 20250 Views

Musk predicts AI will create ‘universal high income’ and make saving money unnecessary

December 17, 20251 Views

Mortgage rates tick higher but remain near 2025 lows

December 17, 20252 Views
Don't Miss

3 Ways to Build a Lasting Legacy of Generosity

By News RoomDecember 17, 2025

Giving is good for your health.At the end of each year, numerous not-for-profit organizations are…

3 Reasons I Hate Crypto — and 3 Reasons I Own It Anyway

December 17, 2025

The Top 10 Jobs You Can Find in the Health Care Industry Now

December 17, 2025

Powell says rate cuts won’t make ‘much of a difference’ for struggling housing sector

December 16, 2025
Facebook Twitter Instagram Pinterest Dribbble
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
© 2025 FintechoPro. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.